For instance, the USP9X inhibitor WP1130 lowers Mcl-1 levels in chronic myelogenous leukemia and enhances sensitivity to apoptosis by facilitating Mcl-1 degradation [79]. Here, USP9X is linked to chronic myelogenous leukemia, BCR-ABL1 positive.